InvestorsHub Logo
Followers 33
Posts 2842
Boards Moderated 2
Alias Born 10/24/2015

Re: None

Thursday, 09/27/2018 6:52:50 PM

Thursday, September 27, 2018 6:52:50 PM

Post# of 296
A neoantigen vaccine (VB10.NEO) and 214 will be tested in 10 patients with SCCHN http://www.vaccibody.com/vaccibody-announces-clinical-collaboration-agreement-with-nektar-therapeutics-for-evaluation-of-vaccibodys-personalized-cancer-neoantigen-vaccine-in-combination-with-nektars-cd-122-b/

A trial with BXCL701 (DPP 8/9 & FAP inhibitor), 214 and a PD-1 inhibitor will be underway in PDAC soon https://ir.bioxceltherapeutics.com/press-releases/detail/54/bioxcel-therapeutics-expands-immuno-oncology-partnership

Also unconfirmed reports of a preclinical collaboration with Affimed.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NKTR News